Granules India Rises on Strong Earnings; Motilal Oswal Eyes ₹670

HEALTHCAREBIOTECH

Overview

Motilal Oswal initiated coverage on Granules India with a 'BUY' recommendation, setting a target price of ₹670. The brokerage cited the company's higher-than-expected revenue, EBITDA, and PAT in the latest quarter, driven by strong performance in formulations (FDF) and intermediates (PFI) segments. Increased off-take and new product launches in Europe also fueled the positive outlook.

Analyst Upgrade Sparks Granules India Rally

Shares of Granules India Ltd. saw renewed investor interest following a positive research report from Motilal Oswal Financial Services. The brokerage firm has reiterated its 'BUY' rating on the pharmaceutical company, projecting a potential upside to ₹670 per share. This optimism is underpinned by Granules India's robust financial performance in the recent quarter, which surpassed analyst expectations across key metrics.

Stellar Quarterly Performance

Granules India delivered a quarter marked by significant beats on revenue, EBITDA, and profit after tax (PAT), exceeding Motilal Oswal's forecasts by 10%, 11%, and 7%, respectively. This outperformance was primarily attributed to strong sales momentum in its finished dosage forms (FDF) and pharmaceutical intermediates (PFI) divisions. The company's ability to scale up sales in key markets like Europe, fueled by higher customer off-take and successful new product introductions, further bolstered its financial results.

Valuation and Outlook

Motilal Oswal values Granules India at 19 times its 12-month forward earnings, a multiple that supports their target price of ₹670. The firm's confidence stems from the company's consistent operational improvements and expanding market reach. Investors are keenly watching Granules India's strategy to sustain this growth trajectory, particularly its efforts in product innovation and geographical expansion, which are critical for achieving the outlined valuation targets.

Disclaimer:This content is for educational and informational purposes only and does not constitute investment, financial, or trading advice, nor a recommendation to buy or sell any securities. Readers should consult a SEBI-registered advisor before making investment decisions, as markets involve risk and past performance does not guarantee future results. The publisher and authors accept no liability for any losses. Some content may be AI-generated and may contain errors; accuracy and completeness are not guaranteed. Views expressed do not reflect the publication’s editorial stance.